Furthermore, Charrua et al. observed that the synergic effects of TRPV1 antagonist (RN1734) and TRPV4 antagonist (SB366791) could reverse the bladder hyperactivity of lipopolysaccharide (LPS)-induced cystitis at very low doses. This evidence concerns the gene TRPV4 and cystitis.